Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company

J&J Innovative Medicine China Appoints New General Manager and Oncology VP

Fineline Cube Feb 13, 2025

Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments...

Company Deals

Liaoning Chengda Biotech to See Actual Controller Change of Controlling Shareholder

Fineline Cube Feb 13, 2025

China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) announced a proposed change in the actual...

Company Drug

Bayer’s Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU

Fineline Cube Feb 13, 2025

Germany-headquartered Bayer (ETR: BAYN) has received marketing approval from the European Medicines Agency (EMA) for...

Company Drug

Livzon Pharmaceutical’s JP-1366 Approved for Peptic Ulcer Study by NMPA

Fineline Cube Feb 13, 2025

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has obtained approval from the National Medical Products...

Company Deals

Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform

Fineline Cube Feb 13, 2025

US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a multi-year partnership with compatriot firm...

Company Medical Device

Lifetech Scientific’s Aortic Stent Graft System Wins NMPA Approval

Fineline Cube Feb 13, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced that it has received market approval from the...

Company Deals

Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer

Fineline Cube Feb 12, 2025

Eli Lilly & Co. (NYSE: LLY) has expanded its collaboration with Australia-based AdvanCell, a clinical-stage...

Company Deals Drug

Eli Lilly Licenses OliX Pharma’s OLX75016 for MASH and Cardiometabolic Diseases

Fineline Cube Feb 12, 2025

Eli Lilly & Co. (NYSE: LLY) has signed a licensing agreement with OliX Pharmaceuticals, Inc....

Company

Gilead Sciences’ Q4 2024 Financials Show 6% Revenue Growth, Driven by HIV and Oncology

Fineline Cube Feb 12, 2025

Gilead Sciences Inc. (NASDAQ: GILD) reported a 6% year-on-year (YOY) increase in global revenues for...

Company Drug

Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study

Fineline Cube Feb 12, 2025

Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the...

Company Drug

Hainan Poly Pharm’s Generic ProHance Wins FDA Approval in US

Fineline Cube Feb 12, 2025

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced that the US Food and Drug...

Company Deals

Kexing Biopharm and Bio-Thera Solutions Form Alliance for Global Expansion

Fineline Cube Feb 12, 2025

China-based Kexing Biopharm (SHA: 688136) and Bio-Thera Solutions Ltd (SHA: 688177) have formed a strategic...

Company Medical Device

MicroPort MedBot’s Toumai Surgical Robot Wins NMPA Approval for Single-Hole Laparoscopy

Fineline Cube Feb 12, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that the National Medical Products Administration...

Company Deals

Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio

Fineline Cube Feb 11, 2025

Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...

Company Drug

J&J’s Rybrevant and Talvey Win Separate NMPA Approvals in China

Fineline Cube Feb 11, 2025

US pharma giant Johnson & Johnson (J&J, NYSE: JNJ) announced receiving marketing approvals from China’s...

Company Drug

Degron Therapeutics’ DEG6498 Receives FDA Clearance for Clinical Trials

Fineline Cube Feb 11, 2025

China-based Degron Therapeutics, a developer of molecular glue-based drugs, announced that the U.S. Food and...

Company Deals

Roche Transfers InterMune and Esbriet to Legacy Pharma in IP Deal

Fineline Cube Feb 11, 2025

Swiss pharma giant Roche (SWX: ROG) has transferred US-based InterMune, Inc., acquired for USD 8...

Company Drug

Bio-Thera Solutions’ BAT1006 Wins NMPA Approval for HER2+ Breast Cancer Trial

Fineline Cube Feb 11, 2025

China’s Bio-Thera Solutions Ltd (SHA: 688177) has received clinical trial approval from the National Medical...

Company Drug

China Resources Double-Crane Pharmaceutical Co., Ltd Receives NMPA Approval for Generic Purinethol

Fineline Cube Feb 11, 2025

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received marketing approval...

Company Drug

Henlius Biotech’s HLX99 Receives FDA Approval for ALS Clinical Study

Fineline Cube Feb 11, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration (FDA)...

Posts pagination

1 … 260 261 262 … 711

Recent updates

  • Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA
  • WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
  • China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration
  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Legal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

Company

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%

Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.